1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- Author
-
R. Labianca, Fortunato Ciardiello, J.-Y. Douillard, Alfredo Falcone, André D'Hoore, C.-H. Köhne, Aziz Zaanan, George Pentheroudakis, Dan Aderka, Nicola Normanno, Takayuki Yoshino, Per Pfeiffer, H.-J. Schmoll, Al B. Benson, J.H.J.M. van Krieken, René Adam, Demetris Papamichael, Paulo M. Hoff, Jens Ricke, R. Salazar, György Bodoky, Harpreet Wasan, Josep Tabernero, Timothy J. Price, Dirk Arnold, Michel Ducreux, Alberto Sobrero, Thomas Gruenberger, Brigette B.Y. Ma, Axel Grothey, E. Aranda Aguilar, E. Van Cutsem, Karin Haustermans, Volker Heinemann, Pia Österlund, Kei Muro, Arnaud Roth, Eduardo Díaz-Rubio, Pierre Laurent-Puig, Andrés Cervantes, Alberto Bardelli, Wim J.G. Oyen, Julien Taieb, C.J.A. Punt, Sabine Tejpar, Tim Maughan, Werner Scheithauer, Van Cutsem, E, Cervantes, A, Adam, R, Sobrero, A, Van Krieken, Jh, Aderka, D, Aranda Aguilar, E, Bardelli, A, Benson, A, Bodoky, G, Ciardiello, Fortunato, D'Hoore, A, Diaz Rubio, E, Douillard, Jy, Ducreux, M, Falcone, A, Grothey, A, Gruenberger, T, Haustermans, K, Heinemann, V, Hoff, P, Köhne, Ch, Labianca, R, Laurent Puig, P, Ma, B, Maughan, T, Muro, K, Normanno, N, Österlund, P, Oyen, Wj, Papamichael, D, Pentheroudakis, G, Pfeiffer, P, Price, Tj, Punt, C, Ricke, J, Roth, A, Salazar, R, Scheithauer, W, Schmoll, Hj, Tabernero, J, Taïeb, J, Tejpar, S, Wasan, H, Yoshino, T, Zaanan, A, Arnold, D. 4. 5., and Oncology
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Evidence-based practice ,Bevacizumab ,Colorectal cancer ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,Guidelines as Topic ,colorectal cancer ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] ,03 medical and health sciences ,chemistry.chemical_compound ,Clinical practice guidelines ,Consensus ,ESMO ,Hematology ,0302 clinical medicine ,Guia de Práctica Clínica ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Molecular Targeted Therapy ,Neoplasm Metastasis ,Intensive care medicine ,Tipiracil ,Neoplasias Colorrectais/tratamento ,FOLFOXIRI ,business.industry ,clinical practice guidelines ,consensus ,Cancer ,Prognosis ,medicine.disease ,Debulking ,Chemotherapy regimen ,digestive system diseases ,3. Good health ,030104 developmental biology ,Practice Guideline ,chemistry ,Colorectal Neoplasms/therapy ,030220 oncology & carcinogenesis ,Colorectal Neoplasms ,business ,clinical practice guideline ,medicine.drug - Abstract
Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
- Published
- 2016